The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 104, Issue , 1997, Pages 4-13

  Crook, D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN;

CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG IMPLANT; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FIRST PASS EFFECT; HEMOSTASIS; HUMAN; LIPOPROTEIN METABOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION ROUTES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HEMOSTASIS; HUMANS; LIPOPROTEINS; LIVER; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS;

EID: 0030728248     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1997.tb11561.x     Document Type: Article

References (84)

1. Nachtigall LE. Emerging delivery systems for estrogen replacement: Aspects of transdermal and oral delivery. Am J Obstet Gynecol 1995; 173: 993–997.
2. Jewelewicz R. New developments in topical estrogen therapy. Fertil Steril 1997; 67: 1–12.
3. Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992; 48: 276–308.
4. Stampfer MJ, Grodstein F. Role of hormone replacement in cardiovascular disease. In Treatment of the postmenopausal woman: Basic and clinical aspects. Lobo RA, ed. Raven Press Ltd, New York, USA; 1994: 223–233.
5. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–1109.
6. Crook D. Postmenopausal hormone replacement therapy, lipoprotein metabolism and coronary heart disease. J Cardiovasc Pathol 1996; 28 (Suppl. 5): S40–S45.
7. Lobo RA. Estrogen and the risk of coagulopathy. Am J Med 1992; 92: 283–285.
8. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–987.
9. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–980.
10. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–983.
11. Gutthann SP, Rodriguez LAG, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study. Br Med J 1997; 314: 796–800.
12. Crook D. Do different oral contraceptives differ in their effects on cardiovascular disease? Br J Obstet Gynaecol 1997; 104: 516–520.
13. de Ziegler D. Is the liver a target organ for estrogen? In The Menopause and Hormonal Replacement Therapy. Sitruk-Ware R, Utian WH, eds. Marcel Dekker Inc, New York, USA; 1991: 201–226.
14. O’Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35(9 Suppl): 18S–24S.
15. Chetkowski RJ, Meldrum DR, Steingold KA et al. Biological effects of transdermal estradiol. N Engl J Med 1986; 314: 1615–1620.
16. Studd JWW, Smith RNJ. Oestradiol and testosterone implants in menopause management. In: Baillière’s Clinical Endocrinology and Metabolism. Burger HG, ed. The Menopause. 1993; 7: 203–224.
17. Marsh MS, Whitehead MI. The practicalities of hormone replacement therapy. In Bailliere’s Clinical Endocrinology and Metabolism. Burger HG, ed. The Menopause. 1993; 7: 183–202.
18. de Ziegler D, Seidler L, Scharer E, Bouchart P. [Non-oral administration of progesterone: Experiences and possibilities of the transvaginal route]. Schweizerische Rundschau fur Medizin Praxis 1995; 86: 127–33 (In German).
19. Fridriksdottir H, Loftsson T, Gudmundsson JA, Bjarnason GJ, Kjeld M, Thorsteinsson T. Design and in vivo testing of 17 beta-estradiol-HP beta CD sublingual tablets. Pharmazie 1996; 51: 39–42.
20. Mitragotri S, Blankschtein D, Langer R. Transdermal drug delivery using low-frequency sonophoresis. Pharmaceutical Research 1996; 13: 411–420.
21. Raudaskoski T, Lahti E, Kauppila A, Apaja-Sarkkinen M, Laatikainen T. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. Am J Obstet Gynecol 1995; 172: 114–119.
22. Pallas KG, Holzwarth GJ, Stern MP et al. The effect of conjugated estrogens on the renin-angiotensin system. J Clin Endocrinol Metab 1997; 44: 1061–1068.
23. Lobo R. Cardiovascular implications of estrogen replacement therapy. Am J Obstet Gynecol 1990; 75(Suppl): 18–25.
24. Weir RG, Briggs E, Mack A, Naismith L, Taylor L, Wilson E. Blood pressure in women taking oral contraceptives. Br Med J 1974; i: 533–535.
25. Lip GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Human Hypertens 1994; 8: 491–494.
26. Sands RH, Studd JWW, Crook D, Warren JB, Cruickshank J, Coats A. The effect of estrogen on blood pressure in hypertensive postmenopausal women. Menopause 1997; 4: 115–119.
27. Proudler AJ, Crook D, Godsland IF, Collins P, Rosano GMC, Stevenson JC. Serum angiotensin 1 — converting enzyme (ACE) in women with cardiological syndrome X: Relation with blood pressure, and lipid and carbohydrate metabolic risk markers for coronary heart disease. J Clin Endocrinol Metab 1995; 80: 696–699.
28. Schunkert H, Danser AHJ, Hense H-W, Derkx FHM, Kürzinger S, Riegger GAJ. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997; 95: 39–45.
29. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166–171.
30. Hassager C, Riis BJ, Strøm V, Guyenne TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987; 76: 753–758.
31. Notelovitz M. Hormone therapy and haemostasis. In Treatment of the Postmenopausal Woman: Basic and clinical aspects. Lobo RA, ed. Raven Press Ltd, New York, USA; 1994: 271–281.
32. Winkler UH. Menopause, hormone replacement therapy and cardiovascular disease: A review of haemostaseological findings. Fibrinolysis 1992; 6 (Suppl. 3): 5–10.
33. Koh KK, Mincemoyer R, Bui MN et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683–690.
34. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–461.
35. Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: Principal results of the North wick Park Heart Study. Lancet 1986; ii: 533–537.
36. Winkler UH, Kramer R, Kwee B, Schindler AE. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: Comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens]. Zentralblatt fur Gynakologie 1995; 117: 540–548 (In German).
37. The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study. Thromb Haemostasis 1996; 75: 476–480.
38. Lindoff C, Peterson F, Lecander I, Martinsson G, Astedt B. Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease. Maturitas 1996; 24: 43–50.
39. Aune B, Oian P, Omsjo I, Osterud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood — a beneficial effect on atherogenesis and thrombus formation? Am J Obstet Gynecol 1995; 173: 1816–1820.
40. Godsland IF. Female sex hormones and gonadal steroids. J Intern Med 1996; 240 (Suppl. 738): 3–60.
41. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stancxyk FZ, Lobo RA. A possible bimodal effect on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60: 664–667.
42. Lindheim SR, Duffy DM, Kojima T, Vijod MA, Stancxyk FZ, Lobo RA. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 1994; 62: 1176–1180.
43. Cagnacci A, Soldani R, Carriero P, Paoletti A, Fioretti P, Melis G. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992; 74: 1396–1400.
44. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: Effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997; 104: 298–304.
45. Sattar N, Jaap AJ, MacCuish AC. Hormone replacement therapy and cardiovascular risk in postmenopausal women with NIDDM. Diabetic Medicine 1996; 13: 782–788.
46. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
47. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor? Diabetes Care 1995; 18: 1299–1304.
48. Modan M, Or J, Karasik A el al. Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease. Circulation 1991; 84: 1165–1175.
49. Krauss RM. Lipids and lipoproteins and effects of hormone replacement. In Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Lobo RA, ed. Raven Press Ltd, New York, USA; 1994: 235–42.
50. Gevers Leuven JA. Sex steroids and lipoprotein metabolism. Pharmac Ther 1994; 64: 99–126.
51. Newnham HH. Oestrogens and atherosclerotic vascular disease — lipid factors. In Baillière’s Clinical Endocrinology and Metabolism. Burger HG, ed. The Menopause. 1993; 7: 61–93.
52. Crook D, Stevenson JC. Transdermal hormone replacement therapy, serum lipids and lipoproteins. Br J Clin Practice 1996; 86 (Suppl.): 17–21.
53. Westerveld HT, Kock LAW, van Rijn HJM, Erkelens DW, de Bruin TWA. 17β-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1995; 80: 249–253.
54. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–220.
55. Crook D. HRT and hypertriglyceridemias. In The Prescriber’s Guide to Hormone Replacement Therapy. Whitehead MI, ed. Parthenon Press, UK (in press).
56. de Lignieres B, Basdevant A, Thomas G et al. Biological effects of estradiol-17β in postmenopausal women: Oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536–541.
57. Crook D, Cust MP, Gangar KF et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: Effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950–955.
58. Mattsson L-A, Samsioe G, von Schoultz B, Uvebrant M, Wiklund I. Transdcrmally administered oestradiol combined with oral medroxyprogesterone acetate: The effects on lipoprotein metabolism in postmenopausal women. Br J Obstet Gynaecol 1993; 100: 450–453.
59. Campos H, Sacks FM, Walsh BW, Schiff I, O’Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 1993; 42: 1153–1158.
60. Sack MN, Rader DJ, O’Cannon R. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269–270.
61. Taskinen MR, Puolakka J, Pyorala T et al. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol 1996; 16: 1215–1221.
62. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993: 153: 2209–2216.
63. Stanczyk FZ, Shoupe D, Nunez V et al. A randomized comparison of non oral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988; 159: 154–156.
64. Lindgren R, Berg G, Hammar M, Larsson-Cohn U, Olsson AG. Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate. Eur J Obstet Gynecol Reprod Biol 1992; 47: 213–221.
65. Manassiev N, Ross D, Crook D et al. Randomised double-blind double-dummy placebo-controlled study of the lipid and lipoprotein effects of transdermal and oral oestrogens. Acta Obstet Gynecol Scand 1997; 76: (Suppl. 167): 85.
66. Cheang A, Sitruk-Ware R, Samsoie G. Transdermal oestradiol and cardiovascular risk factors. Br J Obstet Gynaecol 1994; 101: 571–581.
67. Basdevant A, de Lignieres B, Simon P, Blache D, Ponsin G, Guy-Grand B. Hepatic lipase activity during oral and parenteral 17β-estradiol replacement therapy: High density lipoprotein increase may not be antiatherogenic. Fertil Steril 1991; 55: 1112–1117.
68. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal oestrogen on high density lipoprotein metabolism. J Lipid Res 1994; 35: 2083–2093.
69. Liu AC, Lawn RM, Verstuyft JG, Rubin EM. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein(a) in transgenic mice. J Lipid Res 1994; 35: 2263–2267.
70. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women — a clinical research center study. J Clin Endocrinol Metab 1996; 81: 2250–2256.
71. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older poslmenopausal women: A clinical research center study. J Clin Endocrinol Metabolism 1996; 81: 2848–2853.
72. D’Amato G, Cavallini A, Mangini V, Misciagna G. Serum and bile lipid levels in a postmenopausal woman after percutaneous and oral natural estrogens. Am J Obstet Gynecol 1989; 160: 600–601.
73. van Erpecum KJ, van Berge Henegouwen GP, Verschoor L, Stoelwinder B, Willikens FL. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100: 482–488.
74. Adams MR, Kaplan JR, Manuck SB et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Arteriosclerosis 1990; 10: 1051–1057.
75. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc NatlAcad Sci 1996; 93: 10022–10027.
76. Williams JK, Adams M, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992; 20: 452–457.
77. de Ziegler D, Bessis R, Frydman R. Vascular resistance of uterine arteries: Physiological effects of estradiol and progesterone. Fertil Steril 1991; 55: 775–779.
78. Gangar KF, Vyas S, Crook D, Meire H, Whitehead MI. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 839–842.
79. Penotti M, Farina M, Castiglioni E et al. Alteration in the pulsatility index values of the internal carotid and middle cerebral arteries after suspension of postmenopausal hormone replacement therapy: A randomized crossover study. Am J Ohstet Gynecol 1996; 175: 606–611.
80. Reis SE, Gloth ST, Blutnenthal RS et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholinc in postmenopausal women. Circulation 1994; 89: 52–60.
81. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial infarction in women with coronary artery disease. Lancet 1993; 342: 133–136.
82. Holdright DR, Sullivan AK, Wright CA, Sparrow JL, Cunningham D, Fox KM. Acute effect of oestrogen replacement therapy on treadmill performance in postmenopausal women with coronary artery disease. Eur Heart J 1995; 16: 1566–1570.
83. Cicinelli E, Ignarro LJ, Lograno M, Matteo G, Falco N, Schonauer LM. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 1997; 67: 63–66.
84. Mendelsohn ME, Kara RH. Estrogen and the blood vessel wall. Curr Op Cardiology 1994; 9: 619–626.